Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning

International Journal of Hematology

Volumn 89, Issue 4, 2009, Pages 538-545

  Mizumoto, Chisaki ^a   Kanda, Junya ^a   Ichinohe, Tatsuo ^a   Ishikawa, Takayuki ^a   Matsui, Masashi ^a   Kadowaki, Norimitsu ^a   Kondo, Tadakazu ^a   Imada, Kazunori ^b   Hishizawa, Masakatsu ^a   Kawabata, Hiroshi ^a   Nishikori, Momoko ^a   Yamashita, Kouhei ^a   Takaori Kondo, Akifumi ^a   Hori, Toshiyuki ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

Bone marrow transplantation; Graft versus host disease; Mycophenolate mofetil; Reduced intensity conditioning; Unrelated donor

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; ASEPTIC MENINGITIS; BACTEREMIA; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORTALITY; NEUTROPENIC ENTEROCOLITIS; ORGAN DONOR; OVERALL SURVIVAL; PHLEGMON; REDUCED INTENSITY CONDITIONING; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION; ACUTE DISEASE; CHRONIC DISEASE; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LEUKEMIA; MIDDLE AGED; SURVIVAL RATE;

ACUTE DISEASE; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; SURVIVAL RATE; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 67449123238     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0306-5     Document Type: Article

References (42)

1. M Aoudjhane M Labopin NC Gorin A Shimoni T Ruutu HJ Kolb 2005 Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) Leukemia 19 2304 2312 10.1038/sj.leu.2403967 (Pubitemid 41748028)
2. EP Alyea HT Kim V Ho C Cutler J Gribben DJ DeAngelo 2005 Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age Blood 105 1810 1814 10.1182/blood-2004-05-1947 (Pubitemid 40223707)
3. R Martino S Iacobelli R Brand T Jansen A van Biezen J Finke 2006 Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood 108 836 846 10.1182/blood-2005-11-4503 (Pubitemid 44154615)
4. R Rodriguez A Nademanee N Ruel E Smith A Krishnan L Popplewell 2006 Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma Biol Blood Marrow Transplant 12 1326 1334 10.1016/j.bbmt.2006.08.035 (Pubitemid 44858267)
5. M Bornhäuser C Thiede U Platzbecker A Jenke A Helwig R Plettig 2001 Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients Clin Cancer Res 7 2254 2262 (Pubitemid 32751622)
6. MB Maris D Niederwieser BM Sandmeier B Storer M Stuart D Maloney 2003 HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 102 2021 2030 10.1182/blood-2003-02-0482 (Pubitemid 37122375)
7. S Giralt B Logan D Rizzo MJ Zhang K Ballen C Emmanoulides 2007 Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program Biol Blood Marrow Transplant 13 844 852 10.1016/j.bbmt.2007.03.011 (Pubitemid 46902440)
8. Y Onishi S Mori S Kusumoto K Sugimoto D Akahane Y Morita-Hoshi 2007 Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation Int J Hematol 85 256 263 10.1532/IJH97.06199 (Pubitemid 46686587)
9. GB Vogelsang S Arai 2001 Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings Bone Marrow Transplant 27 1255 1262 10.1038/sj.bmt.1703076 (Pubitemid 32655393)
10. AC Allison EM Eugui 2005 Mechanism of action of mycophenolate mofetil in preventing acute and chronic allograft rejection Transplantation 80 Suppl 2 S181 S190 10.1097/01.tp.0000186390.10150.66 (Pubitemid 41552905)
11. PA McSweeney D Niederwieser JA Shizuru BM Sandmeier AJ Molina DG Maloney 2001 Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 3390 3400 10.1182/blood.V97.11.3390
12. Y Nieto N Patton T Hawkins R Spearing SI Bearman RB Jones 2006 Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation Biol Blood Marrow Transplant 12 217 225 10.1016/j.bbmt.2005.10.012 (Pubitemid 43138016)
13. B Bolwell R Sobecks B Pohlman S Andresen L Rybicki E Kuczkowsky 2004 A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation Bone Marrow Transplant 34 621 625 10.1038/sj.bmt.1704647 (Pubitemid 39341543)
14. RA Nash L Johnston P Parker JS McCune B Storer JT Slattery 2005 A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 11 495 505 10.1016/j.bbmt.2005.03.006 (Pubitemid 40862446)
15. D Przepiorka C Ippoliti I Khouri M Woo R Mehra D Le Bherz 1996 Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation Blood 88 4383 4389
16. R Wong SA Giralt T Martin DR Couriel A Anagnostopoulos C Hosing 2003 Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years Blood 102 3052 3059 10.1182/blood-2003-03-0855 (Pubitemid 37248883)
17. M Tanabe S Todo N Murase W Irish H Miyazawa S Fujisaki 1995 Therapeutic synergism between low-dose FK506 and antimetabolites in rat allogeneic heart transplantation Transplant Proc 27 364 365
18. DE Eckhoff BM McGuire LR Frenette JL Contreras SL Hudson JS Bynon 1998 Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation Transplantation 65 180 187 10.1097/00007890-199801270-00006
19. D Przepiorka D Weisdorf P Martin HG Klingemann P Beatty J Hows 1995 1994 consensus conference on acute GVHD grading Bone Marrow Transplant 15 825 828
20. KM Sullivan E Agura C Anasetti FR Appelbaum C Badger S Bearman 1991 Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Hematol 28 250 259
21. BD Cheson PA Cassileth DR Head CA Schiffer JM Bennett CD Bloomfield 1990 Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia J Clin Oncol 8 813 819
22. BD Cheson JM Bennett H Kantarjian A Pinto CA Schiffer SD Nimer 2000 Report of an international working group to standardize response criteria for myelodysplastic syndrome Blood 96 3671 3674
23. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors 1999 Report of an International workshop to standardize response criteria for non-Hodgkin's lymphomas NCI sponsored International Working Group J Clin Oncol 17 1244 1253
24. J Bladé D Samson D Reece J Apperley B Björkstrand G Gahrton 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation Br J Haematol 102 1115 1123 10.1046/j.1365-2141.1998.00930.x (Pubitemid 28435189)
25. Y Yamada M Tomonaga H Fukuda S Hanada A Utsunomiya M Tara 2001 A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303 Br J Haematol 113 375 382 10.1046/j.1365-2141.2001.02737.x (Pubitemid 32523141)
26. E Sakaida C Nakaseko A Harima A Yokota R Cho Y Saito 2003 Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect Blood 102 4236 4242 10.1182/blood-2002-10-3289 (Pubitemid 37487013)
27. Y Morishima K Sasazuki H Inoko T Juji T Akaza K Yamamoto 2002 The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors Blood 99 4200 4206 10.1182/blood.V99.11.4200 (Pubitemid 35332066)
28. T Kitawaki N Kadowaki T Ishikawa T Ichinohe T Uchiyama 2003 Compromised recovery of natural interferon-α/β-producing cells after allogeneic hematopoietic stem cell transplantation complicated by acute graft-versus-host disease and glucocorticoid administration Bone Marrow Transplant 32 187 194 10.1038/sj.bmt.1704093 (Pubitemid 36903443)
29. T Saito S Yoshioka Y Iinuma S Takakura N Fujihara T Ichinohe 2008 Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit Eur J Clin Microbiol Infect Dis 27 209 216 10.1007/s10096-007-0428-8
30. TA Gooley W Leisenring JA Crowley BE Storer 1999 Estimation of failure probabilities in the presence of competing risks: new representation of old estimators Stat Med 18 665 706 10.1002/(SICI)1097-0258(19990330)18:6<695:: AID-SIM60>3.0.CO;2-O (Pubitemid 29126745)
31. M Körbling P Anderlini 2001 Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 98 2900 2908 10.1182/blood.V98.10.2900
32. BR Dey J Shaffer AJ Yee S McAfee M Caron K Power 2007 Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen Bone Marrow Transplant 40 19 27 10.1038/sj.bmt.1705688 (Pubitemid 47018410)
33. R Storb C Yu JL Wagner HJ Deeg RA Nash HP Kiem 1997 Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 3048 3054
34. LP Koh CS Chen BC Tai WY Hwang LK Tan HY Ng 2007 Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy Biol Blood Marrow Transplant 13 790 805 10.1016/j.bbmt.2007.03.002 (Pubitemid 46902434)
35. S Ozawa C Nakaseko M Nishimura A Maruta R Cho C Ohwada 2007 Chronic graft-versus-host-disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program Br J Haematol 137 142 151 10.1111/j.1365-2141.2007.06543.x (Pubitemid 46474715)
36. L Hambach M Stadler E Dammann A Ganser B Hertenstein 2002 Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation Bone Marrow Transplant 29 903 906 10.1038/sj.bmt.1703583 (Pubitemid 34814698)
37. M Baudard A Vincent P Moreau MF Kergueris JL Harousseau N Milpied 2002 Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients Bone Marrow Transplant 30 287 295 10.1038/sj.bmt.1703633
38. L Giaccone JS McCune MB Maris TA Gooley BM Sandmeier JT Slattery 2005 Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation Blood 106 4381 4388 10.1182/blood-2005-06-2217 (Pubitemid 41775952)
39. S Lange SC Mueller S Altmann M Dahlhaus B Drewelow M Freund 2008 Pharmacokinetics of oral mycopheolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic stem cell transplantation Bone Marrow Transplant 41 667 674 10.1038/sj.bmt.1705958
40. P Jacobson K Green J Rogosheske C Brunstein B Ebeling T DeFor 2007 Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation J Clin Pharmacol 47 6 12 10.1177/ 0091270006295064 (Pubitemid 44973992)
41. T van Gelder J Klupp MJ Barten U Christians RE Morris 2001 Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid Ther Drug Monit 23 119 128 10.1097/00007691-200104000-00005 (Pubitemid 32240138)
42. H Kagaya M Miura S Satoh K Inoue M Saito T Inoue 2008 No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients J Clin Pharm Ther 33 193 201 10.1111/j.1365-2710.2008.00906.x (Pubitemid 351341413)